Jump to content

DHAP (chemotherapy)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Hazard-Bot (talk | contribs) at 18:13, 7 March 2016 (Bot: Adding {{Research help|Med}}; please leave feedback/comments at Wikipedia talk:Research help #ResHelp). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory Non-Hodgkin lymphoma and Hodgkin disease.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplant. In combination with anti-CD20 monoclonal antibody Rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

[R]-DHAP regimen consists of:

  1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
  2. (D)examethasone, a glucocorticoid hormone
  3. (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
  4. (P)latinol (cisplatin), a platinum-based antineoplastic agent with an alkylating mechanism;

Dosing regimen

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 0
(D)examethasone 40 mg PO qd Days 1-4
(H)igh-dose Ara-C - cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 2, every 12 hours
(P)latinol (cisplatin) 100 mg/m2 IV infusion over 24 hrs Day 1

References

Template:Research help

  1. ^ Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
Retrieved from "https://en.wikipedia.org/w/index.php?title=DHAP_(chemotherapy)&oldid=708804736"